Clinical Trial Update: Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and bioequivalence of pimecrolimus 1% cream vs Elidel R for mild to moderate atopic dermatitis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Elidel R (pimecrolimus)
• Pimecrolimus Cream 1% (pimecrolimus)

Snippet

Sponsor: Par Pharmaceutical, Inc. | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED